Celyad SA (NASDAQ: CYAD) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Celyad SA and Aptose Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celyad SA 0 0 1 0 3.00
Aptose Biosciences 0 1 4 0 2.80

Celyad SA presently has a consensus target price of $49.00, indicating a potential downside of 8.18%. Aptose Biosciences has a consensus target price of $7.75, indicating a potential upside of 416.67%. Given Aptose Biosciences’ higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Celyad SA.

Profitability

This table compares Celyad SA and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celyad SA N/A N/A N/A
Aptose Biosciences N/A -145.95% -124.12%

Risk and Volatility

Celyad SA has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Valuation and Earnings

This table compares Celyad SA and Aptose Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Celyad SA $13.43 million 37.68 -$23.88 million N/A N/A
Aptose Biosciences N/A N/A -$12.34 million ($0.73) -2.05

Aptose Biosciences has higher revenue, but lower earnings than Celyad SA.

Insider & Institutional Ownership

4.1% of Celyad SA shares are owned by institutional investors. Comparatively, 4.5% of Aptose Biosciences shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aptose Biosciences beats Celyad SA on 5 of the 9 factors compared between the two stocks.

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Aptose Biosciences Company Profile

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.